Vyaire Medical Oy GSLMCO310 Vital Signs™

Zoll M series Biphasic 200 Joules Max Defibrillator. Battery and Cables Included.

FeetMe Evaluation mobileAndroid application version 3.Y.Z.

Tempus ECG-AF is a cardiovascular machine learning-based notification software intended to analyze recordings of 12-lead ECG devices from patients 65 years of age and older. The software employs machine learning techniques to analyze ECG recordings and detect signs associated with a patient experiencing atrial fibrillation and/or atrial flutter (collectively referred to as AF) within the next 12 months. The device is designed to extract otherwise unavailable information from ECGs conducted under the standard of care, to help health care providers better identify patients who may be at risk for undiagnosed AF in order to evaluate them for referral of further diagnostic follow up and address the unmet need of reducing the number of undiagnosed AF patients.

Adult Oral/Nasal CO2 Sampling with O2 Delivery Cannula for CapnoFlex Module

Pediatric Oral/Nasal CO2 Sampling with O2 Delivery Cannula for CapnoFlex Module

SUTURE ANCHOR, MINI CORKSCREW FT

Infant/Neonatal Airway Adapter for CapnoFlex Module

SUTURE ANCHOR, MICRO CORKSCREW FT

Zoll M series Biphasic 200 Joules Max Defibrillator. Battery and Cables Included.

FeetMe Evaluation mobileAndroid application version 3.Y.Z.

Tempus ECG-AF is a cardiovascular machine learning-based notification software intended to analyze recordings of 12-lead ECG devices from patients 65 years of age and older. The software employs machine learning techniques to analyze ECG recordings and detect signs associated with a patient experiencing atrial fibrillation and/or atrial flutter (collectively referred to as AF) within the next 12 months. The device is designed to extract otherwise unavailable information from ECGs conducted under the standard of care, to help health care providers better identify patients who may be at risk for undiagnosed AF in order to evaluate them for referral of further diagnostic follow up and address the unmet need of reducing the number of undiagnosed AF patients.